250 - Long-Acting Lipoglycopeptides: Time to Connect the Dots?

Saturday, October 19, 2024

1:45 PM – 3:00 PM US PT

Location: 408 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Manjunath Pai, PharmD

Professor of Clinical Pharmacy
University of Michigan
Ann Arbor, MI, United States
Ryan Mynatt, PharmD (he/him/his)

Clinical Pharmacist, Infectious Diseases & Outpatient Parenteral Antimicrobial Therapy (OPAT)
University of Kentucky
Lexington, KY, United States

Faculty(s)

Louise-Marie Oleksiuk, PharmD

Clinical Pharmacist in Infectious Diseases and Antimicrobial Stewardship
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
Ryan Moenster, Pharm.D., FIDSA (he/him/his)

Professor of Pharmacy Practice/Clinical Pharmacy Specialist
Pharmacy Practice/Pharmacy Services
St. Louis College of Pharmacy at UHSP/VA St. Louis HCS
St. Louis, MO, United States
Thomas Holland, MD

Associate Professor, Department of Medicine, Division of Infectious Diseases
Duke University Medical Center
Durham, NC, United States

Disclosure(s):

Manjunath P. Pai, PharmD: No financial relationships to disclose

Ryan P. Mynatt, PharmD: No financial relationships to disclose

Louise-Marie Oleksiuk, PharmD: No financial relationships to disclose

Ryan P. Moenster, Pharm.D., FIDSA: Melinta Therapuetics: Grant/Research Support (Terminated, July 31, 2023), Honoraria (Terminated, July 31, 2023)

Thomas L. Holland, MD: Karius, Inc: Advisor/Consultant

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the challenges and opportunities for the use of lipoglycopeptides;
identify patients populations most like to benefit from the use of lipoglycopeptides;
recommend the use of lipoglycopeptides based on their respective institutional needs.

Presentations:

1:45 PM – 2:10 PM US PT

Emergency and outpatient implementation of Dalbavancin use
Speaker: Louise-Marie Oleksiuk, PharmD – University of Pittsburgh Medical Center
2:10 PM – 2:35 PM US PT

Inpatient use of Oritavancin for difficult-to-treat infections
Speaker: Ryan P. Moenster, Pharm.D., FIDSA (he/him/his) – St. Louis College of Pharmacy at UHSP/VA St. Louis HCS
2:35 PM – 3:00 PM US PT

Dalbavancin as an option for treatment of S. aureus bacteremia
Speaker: Thomas L. Holland, MD – Duke University Medical Center